SAAVY
DEAD

Serial Number

90513988

Owner

LogicBio Therapeutics, Inc.

Attorney

Maury M. Tepper, III

Filing Date

Feb 5, 2021

Add to watchlist:

No watchlists yet
View on USPTO

SAAVY Trademark

Serial Number: 90513988

SAAVY is a trademark filed by LogicBio Therapeutics, Inc. on February 5, 2021. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

LogicBio Therapeutics, Inc. (5 trademarks)

65 Hayden Ave
Lexington, MA 02421

Entity Type: 03

Trademark Details

Filing Date

February 5, 2021

Registration Date

Not Registered

Published for Opposition

March 29, 2022

Goods & Services

Pharmaceutical preparations for gene therapy and gene editing; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; viral vectors, non-viral vectors, gene therapy vectors all for medical purposes in gene therapy; biotechnological platform technology, namely, biological nanoparticles for gene delivery to biological cells that includes adeno-associated viral (AAV) vectors to provide a platform for specific expression of biologics with therapeutic effect in gene therapy; drug delivery agents consisting of compounds comprised of proteins in the form of capsids and particles that facilitate the delivery of a wide range of pharmaceuticals; drug delivery agents, in the form of injectable solutions, intravenous fluids, intracerebral solutions, intrathecal solutions, intracisternal solutions, intraocular solutions, intranasal solutions, intratracheal solutions, intraarterial solutions, intramuscular solutions, and medicinal infusions in that facilitate the delivery of capsids and particles used for delivery of gene therapy

medical and scientific research in the fields of gene therapy and gene editing; pharmaceutical research services; pharmaceutical drug development services; custom development of biochemical reagents and biological nanoparticles, namely, therapeutic compositions that feature adeno-associated viral (AAV) vectors to provide a platform for specific expression of biologics with therapeutic effect in gene therapy

Filing History

TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Aug 3, 2023 EWAF
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Aug 3, 2023 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Aug 3, 2023 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Aug 3, 2023 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Aug 3, 2023 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Aug 3, 2023 COAR
ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Jun 26, 2023 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Jun 26, 2023 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov 22, 2022 EXRA
SOU EXTENSION 1 GRANTED
Nov 18, 2022 EX1G
SOU EXTENSION 1 FILED
Nov 18, 2022 EXT1
SOU TEAS EXTENSION RECEIVED
Nov 18, 2022 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
May 24, 2022 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 29, 2022 NPUB
PUBLISHED FOR OPPOSITION
Mar 29, 2022 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 9, 2022 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 20, 2022 CNSA
EXAMINER'S AMENDMENT ENTERED
Feb 20, 2022 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Feb 20, 2022 GNEN
EXAMINERS AMENDMENT E-MAILED
Feb 20, 2022 GNEA
EXAMINERS AMENDMENT -WRITTEN
Feb 20, 2022 CNEA
PREVIOUS ALLOWANCE COUNT WITHDRAWN
Feb 20, 2022 ZZZX
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 19, 2022 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 20, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 20, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 20, 2022 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Aug 30, 2021 GNRN
NON-FINAL ACTION E-MAILED
Aug 30, 2021 GNRT
NON-FINAL ACTION WRITTEN
Aug 30, 2021 CNRT
ASSIGNED TO EXAMINER
Aug 29, 2021 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 11, 2021 NWOS
NEW APPLICATION ENTERED
Feb 9, 2021 NWAP